At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 543 enrolled
Drug / intervention
SAGE-217 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating SAGE-217 and Placebo for Depressive Disorder, Major. Completed, enrolled 543 participants across 39 sites.
Detailed Summary
The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartMay 2020
First PostedJun 2020
Primary CompletionMar 2021
Study CompletionApr 2021
TodayJul 2026
First PostedJun 22, 2020
Enrollment StartMay 12, 2020
Primary CompletionMar 26, 2021
Study CompletionApr 21, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.0 years ago
Interventions
SAGE-217drug
SAGE-217 oral capsules.
Placebodrug
SAGE-217 matched-placebo oral capsules.